Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds

DOYLESTOWN, PA / ACCESSWIRE / January 18, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that the

Related Keywords

Australia ,Japan ,United States ,India ,Brazil ,China ,Russia ,Canada ,Russian ,Australian ,Canadian ,Chinese ,Japanese ,Kostenloser Wertpapierhandel ,Thoma Kikis ,Louie Toma ,Indian Economic ,Alembic Pharmaceuticals ,Neuropathix Inc ,Pennsylvania Biotechnology Center ,Sun Pharmaceutical Industries ,National Institutes Of Health ,Drug Administration ,Company Twitter ,Initiative Helping End Addiction ,Development Of Therapies ,European Union ,Securities Exchange ,National Institute Of Neurological Disorders ,National Institute ,Indian Patent ,Benzene Diols ,Chronic Traumatic Encephalopathy ,Epileptic Encephalopathy ,Indian Economic Survey ,Dean Petkanas ,Additional Territories ,Hepatic Encephalopathy ,Neurological Disorders ,National Institutes ,Helping End Addiction Long Term ,Technologies Directed ,Enhanced Pain Management ,Global Neuropathic Pain ,Global Opioids Drug ,Bucks County ,Securities Act ,Securities Exchange Act ,Safe Harbor ,United States Controlled Substances ,Neuropathix ,Eceives ,Patent ,Rant ,Rom ,Novel ,Anti ,Inflammatory ,Compounds ,